GlaxoSmithKline is breaking up its research-and-development team into smaller, more specialized groups in an effort to bypass the bureaucracy that has hampered it from producing many new drugs over the past decade. GSK hopes these groups will imitate the success of smaller biotech companies. However, some analysts have questioned the approach. "The problem with big companies trying to act like biotechs is that people who like the really entrepreneurial culture of a biotech go to biotechs," one health care analyst said.

Related Summaries